checkAd

     109  0 Kommentare Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer - Seite 2

    Arvinas Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding Arvinas’ ability to bring its technology to patients and the potential therapeutic benefits of the product candidates in Arvinas’ PROTAC protein degrader pipeline. The words “believe,” “expect,” “may,” “plan,” “potential,” “will,” “continue,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Arvinas may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements made as a result of various risks and uncertainties, including but not limited to: Arvinas’ approach to the discovery and development of product candidates based on its PROTAC technology platform is unproven, which makes it difficult to predict the time, cost of development and likelihood of successfully developing any products; Arvinas’ ability to protect its intellectual property position; whether cash and cash equivalent resources will be sufficient to fund Arvinas’ foreseeable and unforeseeable operating expenses and capital expenditure requirements; and other important factors discussed in the “Risk Factors” section of the company’s Annual Report on Form 10-K for the year ended December 31, 2023, and subsequent other reports on file with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release reflect current views with respect to future events, and Arvinas assumes no obligation to update any forward-looking statements except as required by applicable law. These forward-looking statements should not be relied upon as representing Arvinas’ views as of any date after the date of this release.

    Arvinas Contacts

    Investor Contact:
    Jeff Boyle, Arvinas Investor Relations
    +1 (347) 247-5089
    Jeff.Boyle@arvinas.com

    Media Contact:
    Kathleen Murphy, Arvinas Communications
    +1 (760) 622-3771
    Kathleen.Murphy@arvinas.com


    Seite 2 von 2



    Aktuelle Themen


    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer - Seite 2 NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) - Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the appointment of Randy Teel, Ph.D., to …